Pharvaris

Yahoo Finance • 8 days ago

What Does Wall Street Think About Pharvaris N.V. (PHVS)?

Pharvaris N.V. (NASDAQ:PHVS) is one of the best small cap stocks to buy with huge upside potential. Morgan Stanley analyst Maxwell Skor reiterated a Buy rating on Pharvaris N.V. (NASDAQ:PHVS) on December 15, setting a $41 price target. Pha... Full story

Yahoo Finance • 20 days ago

This Biotech Fund Just Made a $22 Million Bet on Pharvaris Stock — Is It a Buy?

Key Points Austin-based Saturn V Capital Management acquired 886,332 shares of Pharvaris in the third quarter. Saturn V now holds 886,332 PHVS shares valued at $22.1 million. PHVS is a new addition, accounting for 4.9% of 13F AUM, which p... Full story

Yahoo Finance • 26 days ago

Pharvaris Announces Positive Topline Data from RAPIDe-3 Pivotal Study Confirming Potential of Deucrictibant for On-Demand Treatment of HAE Attacks

Primary endpoint met; median time to onset of symptom relief achieved in 1.28 hours, significantly faster versus placebo (p<0.0001)All secondary efficacy endpoints met (p<0.0001), including End of Progression™1 (median 17.47 minutes) and c... Full story

Yahoo Finance • last month

Biotech Stock Gets Booted in Latest Fund Update

Key Points Sold 1,447,267 shares, a net position change of $110.43 million Post-trade stake: 0 shares, $0 value The position was previously 13.8% of the fund's AUM as of the prior quarter, marking a significant portfolio shift These 10 st... Full story

Yahoo Finance • 2 months ago

Pharvaris Reports Third Quarter 2025 Financial Results and Provides Business Update

Topline data for RAPIDe-3, a pivotal Phase 3 study of deucrictibant immediate-release capsule for the on-demand treatment of HAE attacks, expected in 4Q2025Enrollment in CHAPTER-3, a pivotal Phase 3 study of deucrictibant extended-release... Full story

Yahoo Finance • 2 months ago

Data Supporting the Potentially Differentiated Pharvaris Portfolio Presented at ACAAI 2025 Annual Scientific Meeting

Open-label prophylaxis data supporting the long-term safety profile and sustained benefits of deucrictibant, as well as clinical validation data of a kinin biomarker assay were highlighted in two oral presentationsFinal data from participa... Full story

Yahoo Finance • 5 months ago

Pharvaris stock price target lowered to $52 by Citizens JMP

Investing.com - Citizens JMP lowered its price target on Pharvaris B.V. (NASDAQ:PHVS) to $52.00 from $55.00 on Wednesday, while maintaining a Market Outperform rating on the stock. Currently trading at $21.09, the company shows a strong fi... Full story

Yahoo Finance • 5 months ago

Pharvaris NV (NASDAQ:PHVS) Reports Wider Q2 2025 Loss, Highlights Clinical Trial Progress

PHARVARIS NV (NASDAQ:PHVS [https://www.chartmill.com/stock/quote/PHVS]) REPORTS Q2 2025 EARNINGS: WIDER LOSS THAN EXPECTED, CLINICAL PROGRESS IN FOCUS Pharvaris NV (NASDAQ:PHVS [https://www.chartmill.com/stock/quote/PHVS]) reported a seco... Full story

Yahoo Finance • 5 months ago

Pharvaris Announces Closing of $201.2 Million Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares

ZUG, Switzerland, July 24, 2025 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of those living with... Full story

Yahoo Finance • 5 months ago

Pharvaris prices $175M securities offering

Pharvaris (NASDAQ:PHVS [https://seekingalpha.com/symbol/PHVS]) priced [https://seekingalpha.com/pr/20174484-pharvaris-announces-pricing-of-upsized-175-million-public-offering-of-ordinary-shares-and-pre]an underwritten offering of 8.25 mill... Full story

Yahoo Finance • 6 months ago

Pharvaris stock awaits pivotal HAE therapy data as BofA reiterates Underperform

Investing.com - BofA Securities has reiterated its Underperform rating and $14.00 price target on Pharvaris B.V. (NASDAQ:PHVS), currently trading at $18.68, as the company announced updated timelines for its hereditary angioedema (HAE) the... Full story

Yahoo Finance • 6 months ago

Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025

ZUG, Switzerland, July 10, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of those living with bradykinin-mediate... Full story

Yahoo Finance • 6 months ago

Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit

ZUG, Switzerland, June 27, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-me... Full story

Yahoo Finance • 6 months ago

NodThera Announces Appointment of Elisabeth Björk as Board Member

NodThera Announces Appointment of Elisabeth Björk as Board Member Former SVP at AstraZeneca R&D brings deep expertise in obesity and cardiometabolic research, portfolio strategy development and commercializationAppointment follows commen... Full story

Yahoo Finance • 6 months ago

Pharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat Bradykinin-Mediated Angioedema Attacks at the EAACI Congress

ZUG, Switzerland, June 16, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-me... Full story

Yahoo Finance • 7 months ago

Pharvaris Announces Annual Meeting of Shareholders

ZUG, Switzerland, June 10, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-me... Full story

Yahoo Finance • 7 months ago

Pharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in Bradykinin-Mediated Angioedema

Deucrictibant data shows single-dose durability without symptom reoccurrence in the majority of HAE attacks treatedFirst-ever bradykinin B2 receptor mechanism-on-mechanism prophylactic/on-demand data supports potential for deucrictibant po... Full story

Yahoo Finance • 7 months ago

Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses

ZUG, Switzerland, May 19, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-med... Full story

Yahoo Finance • 8 months ago

Pharvaris Reports First Quarter 2025 Financial Results and Provides Business Update

Enrollment underway in CHAPTER-3, a pivotal Phase 3 study of deucrictibant for prophylaxis of HAE attacks; topline data expected in 2H2026Attack dataset continues to accumulate in RAPIDe-3, a pivotal Phase 3 study of deucrictibant for the... Full story

Yahoo Finance • 9 months ago

Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Target enrollment achieved in RAPIDe-3, a pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, strengthening confidence in clinical timelinesEnrollment underway in CHAPTER-3, a pivotal Phase 3 study of deucric... Full story